This company listing is no longer active
Metacrine Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Metacrine.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 21.1% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Equillium acquires Metacrine to extend cash runway through 2024
Sep 06Metacrine initiated buy at H.C. Wainwright citing novelty in therapeutic platform
Jun 14Metacrine completes enrollment in mid-stage NASH trial
Jun 02Metacrine initiates mid-stage study of MET409 + empagliflozin in diabetes and NASH
Jan 05What Percentage Of Metacrine, Inc. (NASDAQ:MTCR) Shares Do Insiders Own?
Dec 16Metacrine reports Q3 results
Nov 12In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Metacrine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2022 | N/A | -38 | -36 | -36 | N/A |
6/30/2022 | N/A | -51 | -46 | -46 | N/A |
3/31/2022 | N/A | -60 | -49 | -49 | N/A |
12/31/2021 | N/A | -62 | -47 | -47 | N/A |
9/30/2021 | N/A | -59 | -47 | -47 | N/A |
6/30/2021 | N/A | -50 | -43 | -42 | N/A |
3/31/2021 | N/A | -44 | -40 | -40 | N/A |
12/31/2020 | N/A | -37 | -36 | -36 | N/A |
9/30/2020 | N/A | -34 | -33 | -33 | N/A |
6/30/2020 | N/A | -33 | -31 | -31 | N/A |
3/31/2020 | N/A | -31 | -30 | -30 | N/A |
12/31/2019 | N/A | -29 | -28 | -28 | N/A |
3/31/2019 | 1 | -28 | -28 | -27 | N/A |
12/31/2018 | 1 | -26 | -26 | -25 | N/A |
3/31/2018 | 2 | -14 | -12 | -11 | N/A |
12/31/2017 | 1 | -12 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MTCR's forecast earnings growth is above the savings rate (2.1%).
Earnings vs Market: Insufficient data to determine if MTCR's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if MTCR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if MTCR's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if MTCR's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MTCR's Return on Equity is forecast to be high in 3 years time